Lonza Group AG stock (CH0013841017): Morningstar upgrades to buy

Morningstar upgraded Lonza Group AG to buy from hold on Monday, retaining its 550 CHF price target. The stock trades on the Swiss exchange amid a capital adjustment today.

Morningstar upgraded its rating on Lonza Group AG to buy from hold on Monday, while keeping the price target at 550 CHF, according to MarketScreener as of 05/12/2026. Lonza Group AG shares are set for a capital adjustment on the Xetra exchange today, May 12, 2026, per Deutsche Boerse as of 05/12/2026. The stock closed at 483.00 CHF recently, with a consensus target of 673.61 CHF from 24 analysts.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza Group AG
• Sector/industry: Biotechnology & Medical Research
• Headquarters/country: Switzerland
• Core markets: Pharmaceuticals, biotech
• Key revenue drivers: Contract manufacturing, small molecules, biologics
• Home exchange/listing venue: SIX Swiss Exchange (LONN)
• Trading currency: CHF

Lonza Group AG: core business model

Lonza Group AG operates as a contract development and manufacturing organization (CDMO) in the pharmaceuticals and biotechnology sectors. The company provides services from early-stage drug development through commercial manufacturing, focusing on small molecules, biologics, cell and gene therapies, and capsules and health ingredients, according to Morningstar as of 05/12/2026. Lonza serves pharmaceutical companies, biotech firms, academic institutions, and government organizations via long-term supply agreements.

With around 19,299 employees, Lonza emphasizes innovation in complex manufacturing processes. Its business model relies on high barriers to entry in specialized biotech production, supporting steady revenue from multi-year contracts. The company is listed on the SIX Swiss Exchange under ticker LONN.

Main revenue and product drivers for Lonza Group AG

Lonza derives primary revenue from its four segments: small molecules, biologics, cell and gene technologies, and capsules and health ingredients. Biologics and cell/gene segments have grown due to demand for advanced therapies, per Morningstar data published with Q1 2026 figures. Long-term agreements with major pharma clients form the backbone of its CHF 38.96 billion market cap as of recent trading.

Key drivers include expanding capacity for mRNA and gene therapy production, which gained prominence post-pandemic. The capsules division targets consumer health, diversifying from pure pharma exposure. US investors note Lonza's OTC listing as LZAGY, providing access to this Swiss growth story.

Industry trends and competitive position

The CDMO sector benefits from outsourcing trends among big pharma, reducing capex needs. Lonza holds a strong position with its end-to-end capabilities, competing with firms like Catalent and Samsung Biologics. Its economic moat is rated medium by Morningstar, supported by technical expertise in high-value modalities.

Trends like personalized medicine and biosimilars boost demand for Lonza's services. The company traded at CHF 555.40 recently on SIX Swiss Exchange, per Morningstar as of 05/12/2026, reflecting a P/E of 36.54.

Why Lonza Group AG matters for US investors

Lonza Group AG offers US investors exposure to global biotech manufacturing via its OTC ticker LZAGY. With key clients in the US pharma market, Lonza benefits from American R&D spending, which drives over 40% of global biotech innovation. The ADR facilitates trading without direct Swiss exchange access.

Recent analyst upgrades highlight growth potential amid US-centric trends like cell therapies. Lonza's dividend yield of 0.72% adds income appeal for diversified portfolios tracking healthcare.

Conclusion

Lonza Group AG continues to draw attention with Morningstar's recent upgrade to buy and an upcoming capital adjustment. The CDMO leader maintains solid fundamentals in biotech manufacturing, with analyst consensus leaning positive at an average target well above current levels. US investors can track its performance via LZAGY amid ongoing sector tailwinds.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.